Acrux Limited spotlighted its Female Testosterone Metered Dose Transdermal System (MDTS) at the Bioshares Biotech Summit, revealing positive Phase II data and outlining a clear regulatory and commercial roadmap targeting Hypoactive Sexual Desire Disorder (HSDD) in women.
- Phase II results show significant improvement in sexual health
- Phase III trials planned in US and Australia with FDA and TGA feedback
- US HSDD market potential estimated at US$21.3 billion annually
- Proprietary patchless MDTS delivery system offers patient-friendly application
- Co-development partnerships to accelerate clinical and commercial progress
Acrux Targets Untapped Women's Health Market with Female Testosterone
Acrux Limited (ASX:ACR) has put its Female Testosterone Metered Dose Transdermal System (MDTS) front and centre at the Bioshares Biotech Summit, framing it as a potential blockbuster treatment for Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women. This condition, marked by low sexual desire and related emotional distress, affects approximately 4.9 million women in the US alone, representing a significant unmet medical need and a market opportunity estimated at US$21.3 billion annually.
The company’s CEO John Warmbrunn emphasised the therapy’s unique positioning: a “patchless” transdermal spray delivering controlled doses of testosterone, designed specifically for women. This proprietary MDTS technology aims to overcome historical barriers in female hormone therapy, including regulatory hurdles and off-label use of male testosterone formulations.
Clinical Progress and Regulatory Pathway Set
Acrux shared encouraging Phase II clinical trial results showing statistically significant improvements in the mean number of satisfactory sexual events for women using the testosterone spray compared to placebo over 16 weeks. The lead dose group demonstrated a mean increase of two satisfactory events, compared to just 0.53 for placebo, signalling a meaningful clinical benefit.
Building on this, the company has received recent feedback from the US FDA and Australia’s TGA, paving the way for a Phase III pivotal trial. The upcoming study will be a double-blind, placebo-controlled trial measuring sexually satisfying events and sexual desire scores over 24 weeks, with secondary endpoints including female sexual distress. This regulatory clarity is a critical milestone for Acrux’s development timeline.
Strategic Partnerships and Commercialisation Plans
Acrux is pursuing co-development partnerships with women’s health specialist pharmaceutical companies to de-risk the clinical trial process and accelerate market entry. The company already has distribution and product agreements in place, positioning it well to capitalise on growing female testosterone awareness across key global markets.
The presentation highlighted a robust lifecycle strategy, including a new patented MDTS applicator and a companion smartphone app to support patient adherence and expand indications beyond HSDD, such as female sexual interest/arousal disorders and cognitive symptoms related to menopause.
Diversified Portfolio Supports Core Business
Alongside its female testosterone program, Acrux continues to commercialise a diversified portfolio of FDA-registered topical generics in the US, including nitroglycerin and dapsone gels, which provide a stable income base. Licensing deals, such as the recent milestone agreement for Lenzetto® in Australia, further bolster the company’s financial footing.
While the female testosterone therapy is not yet registered for HSDD, Acrux’s focused strategy and proprietary technology could position it as a first-mover in a market segment that has lacked female-specific, evidence-based hormone therapies.
Bottom Line?
Acrux’s clear clinical progress and regulatory engagement set the stage for pivotal Phase III trials, but investors should watch for trial outcomes and partnership developments that will determine the therapy’s commercial viability.
Questions in the middle?
- Will Acrux secure a co-development partner to share Phase III trial risks and costs?
- How will the FDA and TGA respond to Phase III data and what is the expected approval timeline?
- Can Acrux’s MDTS technology capture significant market share amid evolving female hormone therapy standards?